Abstract
Purpose of Review
To discuss the diagnostic approach, treatment options, and future considerations in the management of plasmacytomas, either solitary or in the context of overt multiple myeloma (MM).
Recent Findings
Advanced imaging techniques such as whole-body magnetic resonance imaging and positron emission tomography/computerized tomography are essential for the diagnostic workup of solitary plasmacytomas (SP) to rule out the presence of other disease foci. The role of flow cytometry and clonal plasma cell detection is currently under study together with other prognostic factors for the identification of patients with SP at high risk of progression to overt MM. Solitary plasmacytomas are treated effectively with local radiotherapy whereas systemic therapy is required at relapse. Clonal plasma cells that accumulate at extramedullary sites have distinct biological characteristics. Patients with MM and soft tissue involvement have poor outcomes and should be treated as ultra-high risk.
Summary
A revised definition of SP that distinguishes between true solitary clonal PC accumulations and SP with minimal bone marrow involvement should be considered to guide an appropriate therapeutic and follow-up approach. Future studies should be conducted to determine optimum treatment approaches for patients with MM and paraskeletal or extramedullary disease.
Similar content being viewed by others
References
Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.
Moulopoulos LA, et al. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol. 1993;11(7):1311–5.
Dimopoulos MA, et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96(6):2037–44.
Kilciksiz S, et al. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;2012:895765.
Galieni P, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica. 2000;85(1):47–51.
Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol. 1983;1(4):255–62.
Thumallapally N, et al. Erratum to: Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer. 2017;17(1):443.
McLain RF, Weinstein JN. Solitary plasmacytomas of the spine: a review of 84 cases. J Spinal Disord. 1989;2(2):69–74.
de Waal EG, et al. Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands. Br J Haematol. 2016;175(4):661–7.
Susnerwala SS, et al. Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer. 1997;75(6):921–7.
Remigio PA, Klaum A. Extramedullary plasmacytoma of stomach. Cancer. 1971;27(3):562–8.
Chim CS, et al. Extramedullary sites of involvement in hematologic malignancies: case 3. Hemorrhagic gastric plasmacytoma as the primary presentation in multiple myeloma. J Clin Oncol. 2002;20(1):344–7.
Hill QA, et al. Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood. 2014;124(8):1296–9.
Paiva B, et al. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood. 2014;124(8):1300–3.
Hill, Q.A., et al., Neoplastic plasma cells are demonstrable at bone marrow sites distant to solitary plasmacytoma of bone and predict for progression to multiple myeloma. ASH Annual Meeting Abstracts, 2006. 108(11): p. 3512-.
Hotz MA, et al. Extramedullary solitary plasmacytoma of the head and neck. A clinicopathological study. Ann Otol Rhinol Laryngol. 1999;108(5):495–500.
Bartl R, et al. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987;87(3):342–55.
Caers J, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11(1):10.
Dingli D, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 2006;108(6):1979–83.
Wilder RB, et al. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer. 2002;94(5):1532–7.
Liebross RH, et al. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999;52(3):245–9.
Caers J, et al. The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow-up of multiple myeloma. Haematologica. 2014;99(4):629–37.
Gleeson TG, et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skelet Radiol. 2009;38(3):225–36.
Kropil P, et al. Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol. 2008;18(1):51–8.
Liebross RH, et al. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41(5):1063–7.
Dimopoulos MA, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33(6):657–64.
Fouquet G, et al. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res. 2014;20(12):3254–60.
Nanni C, et al. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo. 2008;22(4):513–7.
Lu YY, et al. FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: a systematic review and meta-analysis. Clin Nucl Med. 2012;37(9):833–7.
Salaun PY, et al. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica. 2008;93(8):1269–71.
Kim PJ, et al. Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys. 2009;74(3):740–6.
Zamagni E, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50–5.
Nanni C, et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006;33(5):525–31.
Cavo M, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206–17.
Warsame R, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol. 2012;87(7):647–51.
Dispenzieri A, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–24.
Caers J, et al. Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. Ann Med. 2013;45(5–6):413–22.
Katodritou E, et al. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. Am J Hematol. 2014;89(8):803–8.
Holland J, et al. Plasmacytoma. Treatment results and conversion to myeloma. Cancer. 1992;69(6):1513–7.
Soutar R, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124(6):717–26.
Barosi G, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica. 2004;89(6):717–41.
Reed V, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011;117(19):4468–74.
Knobel D, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer. 2006;6:118.
Frassica DA, et al. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 1989;16(1):43–8.
Aviles A, et al. Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol. 1996;14(3):111–7.
Bolek TW, Marcus RB, Mendenhall NP. Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys. 1996;36(2):329–33.
Jyothirmayi R, et al. Radiotherapy in the treatment of solitary plasmacytoma. Br J Radiol. 1997;70(833):511–6.
Tsang RW, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys. 2001;50(1):113–20.
Ozsahin M, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64(1):210–7.
Weber, D.M., Solitary bone and extramedullary plasmacytoma. Hematology Am Soc Hematol Educ Program, 2005;373–6.
Alexander MP, Goodkin DE, Poser CM. Solitary plasmacytoma producing cranial neuropathy. Arch Neurol. 1975;32(11):777–8.
Alexiou C, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999;85(11):2305–14.
Burt M, et al. Medical tumors of the chest wall. Solitary plasmacytoma and Ewing’s sarcoma. J Thorac Cardiovasc Surg. 1993;105(1):89–96.
Chang MY, et al. Solitary plasmacytoma of bone. J Formos Med Assoc. 1994;93(5):397–402.
Galieni P, et al. Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol. 1995;6(7):687–91.
Mayr NA, et al. The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol. 1990;17(4):293–303.
Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46.
Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
Delauche-Cavallier MC, et al. Solitary plasmacytoma of the spine. Long-term clinical course. Cancer. 1988;61(8):1707–14.
Dimopoulos MA, et al. Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. Leuk Lymphoma. 2006;47(8):1553–6.
Harwood AR, Knowling MA, Bergsagel DE. Radiotherapy of extramedullary plasmacytoma of the head and neck. Clin Radiol. 1981;32(1):31–6.
Pour L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360–4.
Short KD, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906–8.
Wu P, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009;50(2):230–5.
Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol. 1996;93(2):345–51.
Blade J, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805–12.
Varga C, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169(6):843–50.
Papanikolaou X, et al. Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse. Leuk Lymphoma. 2013;54(7):1459–64.
Weinstock M, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169(6):851–8.
Katodritou E, et al. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leuk Res. 2009;33(8):1137–40.
Chang H, et al. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004;127(3):280–4.
Muchtar E, et al. Myeloma in scar tissue—an underreported phenomenon or an emerging entity in the novel agents’ era? A single center series. Acta Haematol. 2014;132(1):39–44.
Varettoni M, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325–30.
Moreau P, et al. Prospective evaluation of magnetic resonance imaging and [(18)F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM Study. J Clin Oncol. 2017;35(25):2911–8.
Usmani SZ, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819–23.
Zamagni E, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989–95.
Jurczyszyn A, et al. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016;57(9):2071–6.
Gozzetti A, et al. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer. 2012;118(6):1574–84.
Fassas AB, et al. Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma. 2004;45(2):291–300.
Paludo J, et al. Myelomatous Involvement of the Central Nervous System. Clin Lymphoma Myeloma Leuk. 2016;16(11):644–54.
Paubelle E, et al. Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect. Leukemia. 2005;19(9):1702–4.
Patriarca F, et al. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica. 2005;90(2):278–9.
Anagnostopoulos A, et al. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors. Leuk Lymphoma. 2004;45(11):2275–9.
Avigdor A, et al. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma. 2001;42(4):683–7.
Rosinol L, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89(7):832–6.
Sonneveld P, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31(26):3279–87.
Mateos MV, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259–66.
Durie BG, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomized, open-label, phase 3 trial. Lancet. 2017;389(10068):519–27.
San Miguel JF, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.
Barlogie B, et al. The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol. 2007;20(4):761–81.
Rosinol L, et al. Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution. Bone Marrow Transplant. 2015;50(5):658–62.
Laura R, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol. 2006;76(5):405–8.
Durie BG, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–73.
Mateos MV, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438–47.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Dr. Dimopoulos reports personal fees from Amgen, personal fees from Celgene, personal fees from Janssen, and personal fees from Takeda, during the conduct of the study. Dr. KASTRITIS reports personal fees from Amgen, personal fees from Genesis Pharma, personal fees from Janssen, personal fees from Takeda, and personal fees from Prothena, during the conduct of the study. Dr. Fotiou has nothing to disclose.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Multiple Myeloma
Rights and permissions
About this article
Cite this article
Fotiou, D., Dimopoulos, M.A. & Kastritis, E. How We Manage Patients with Plasmacytomas. Curr Hematol Malig Rep 13, 227–235 (2018). https://doi.org/10.1007/s11899-018-0452-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11899-018-0452-z